Introduction
Involvement of the central nervous system (CNS) is a serious and mostly fatal complication of aggressive lymphoma. Because the incidence of CNS disease in diffuse large B-cell lymphoma (DLBCL) is low 1- 6 prophylactic measures have been restricted to patients with disease characteristics empirically found to convey an increased risk of CNS disease. More recently, risk models have been developed derived from analyses of prospective studies. 1,7-10 The efficacy of different forms of CNS prophylaxis has never formally been demonstrated.
Systemic therapy of CD20 expressing lymphomas has changed over recent years; in particular, shortening of the time interval between treatment cycles 11, 12 and the addition of rituximab to CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) 13,14 significantly improved outcome. It is not known how these changes in systemic therapy affect the frequency, clinical picture, and outcome of CNS events.
We analyzed CNS events occurring in elderly patients with aggressive lymphoma treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Our main objectives were to determine the impact of rituximab on CNS events, the consistency of recently identified risk factors, and the role of CNS prophylaxis in patients treated with chemoimmunotherapy.
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Patients and methods
Patients, diagnostic measures, and treatment 1222 elderly patients (61-80 years) with newly diagnosed aggressive B-cell lymphoma were randomized into the RICOVER-60 trial.
15
Patients received six or eight courses of cyclophosphamide, doxorubicin, vincristine, and prednisone administered every two weeks (CHOP-14) with or without eight infusions of rituximab.
Involved-field radiotherapy (36 Gy) was mandatory for patients with initial bulky disease (≥ 7.5 cm) and/or extranodal disease. Further details have recently been published. 15 
CNS disease
A lumbar puncture was required in patients with lymphoma manifestations in the head and neck and in patients with involvement of bone marrow or testes. Diagnostic procedures included evaluation of cytocentrifuge preparations as minimum requirement. Flow cytometry was performed in many instances. The diagnosis of CNS disease was based on the combination of typical CNS symptoms, radiologic findings, and the detection of lymphoma cells in the spinal fluid. CNS involvement with either parenchymal brain lesions, affection of the spinal cord, meningeosis lymphomatosa, or combinations thereof were counted. Whenever CNS disease was clinically suspected, imaging of the brain and/or the spine and a lumbar puncture were performed. CNS prophylaxis CNS prophylaxis was mandatory for patients with infiltration of bone marrow and testes or lymphoma manifestation in the upper neck or head including sinuses, orbita, oral cavity, tongue and salivary glands. Prophylaxis consisted of i.th. MTX (15 mg) followed by folinic acid rescue on days 1 and 5 of the first two cycles.
Statistical analysis
Patients with first recurrence of aggressive lymphoma to the CNS after achieving complete remission (CR), uncertain CR (CRu) or partial remission, and patients with spread of disease to the CNS during first-line therapy were included. The primary endpoint was time to CNS disease For personal use only. on March 30, 2017. by guest www.bloodjournal.org From defined as time from randomization to disease progression in the CNS, treatment failure with CNS involvement at the end of therapy or CNS relapse after CR/ CRu. Secondary endpoints were survival after CNS disease and time to meningeosis. Survival was defined as time from the diagnosis of CNS disease until death from any cause. Time to meningeosis was defined as time from randomization to disease progression with meningeosis, treatment failure with meningeosis or relapse with meningeosis. Patients with parenchymal disease were censored. Time to CNS disease, time to meningeosis, and survival were estimated according to the method of Kaplan and Meier. 16 Estimators at two years are given with 95% confidence limits. For univariate analyses log rank tests were performed, p-values < 0.05 were considered significant. All factors with p<0.1 were included in the multivariate analysis. To identify prognostic factors for CNS disease we used the proportional hazard model. We proceeded in a stepwise approach for including single factors as suggested by Collet. 17 The strength of prognostic factors was estimated by determining relative risks and the corresponding 95% confidence intervals.
All calculations were made in SPSS/PC+ V 11.5. Two thirds of the patients (n=38) with CNS disease showed intracerebral or intraspinal involvement. An isolated meningeosis lymphomatosa was diagnosed in 15 patients (25.9%). Five patients experienced a combined parenchymal and meningeal relapse. In 20 patients (34.5%) CNS disease occurred after a complete remission had been achieved, two patients had an unknown response at the end of therapy. In the remaining 36 patients (62.0%), however, CNS disease was diagnosed together with a PR or -more frequently -with progressive disease.
Overall, 24 patients (41.4%) experienced a CNS event while concurrently diagnosed with systemic disease. Simultaneous CNS and systemic disease was observed more often in patients with parenchymal disease (47.4%) than in patients with meningeosis (26.7%).
The median time interval between diagnosis and CNS disease was 8 months (range:1; 39), median survival after CNS disease was only 2.5 months.
The role of rituximab Twenty-two of 608 patients (3.6%) treated with R-CHOP-14, and 36 of 609 patients (5.9%) not given rituximab experienced a CNS event. Figure 1 shows the Kaplan-Meier estimates for time to CNS disease. The difference for patients treated with or without rituximab is significant (log-rank test, p=0.043).The estimated 2-year incidence of CNS disease was 6.9% (CI 4.5;9.3) after CHOP-14 and 4.1% (CI 2.3; 5.9) after R-CHOP-14. Patients treated with R-CHOP-14 showed a relative risk (RR) for CNS disease of 0.58 (95% CI 0.3;1.0, p=0.046).
In patients given R-CHOP-14, parenchymal CNS disease accounted for 50% of CNS events as compared to 75% in patients receiving CHOP only. Conversely, the percentage of patients with meningeosis increased from 16.7% of CNS events in patients receiving CHOP-14 to 40.9% in patients treated with R-CHOP-14. Only 6 of 22 R-CHOP-14 patients showed simultaneous systemic disease (27.3%) compared to 50% in patients given CHOP. Because treatment of DLBCL now regularly includes rituximab we repeated the risk factor analysis this time considering only patients treated with R-CHOP. 'Involvement of more than one extranodal site' and 'elevated LDH' were significant; 'presence of B-symptoms' was replaced by 'ECOGperformance status'. This risk group (4.8% of patients treated with R-CHOP-14) showed a probability for CNS events at 2 years of 33.5% (CI 12%; 55%) as compared to 2.8% (CI 1%; 4%) in other patients given R-CHOP-14 (figure 2B).
Intrathecal prophylaxis
Two hundred seventy-three patients (22.4%) received i.th. MTX at least during one cycle of chemotherapy and 202 patients (16.6%) received four i.th. injections but only 11 of 58 patients (19.0%) with a CNS event had received i.th. MTX. Unfortunately, patients with involvement of the upper neck could not exactly be evaluated for protocol violation because the case report forms failed to precisely define "upper neck". One hundred twenty of 210 patients (57.1%) with involvement of testes, bone marrow, or head received i.th. MTX as per protocol whereas 90 patients (42.9%) were not treated. The high number of protocol violations was unexpected.
Treating physicians obviously were not convinced that BM involvement (57.5% protocol violations) percentage of CNS events in prophylaxed patients was slightly lower (2.5%) than in patients without CNS prophylaxis (4.4%) but this difference was not significant. In univariate analysis of patients with involvement of testes, bone marrow, or any site adjacent to the skull, the risk of CNS disease was higher for individuals without i.th. prophylaxis -if they had not received rituximab. In contrast, when therapy included rituximab the risk for CNS relapse was significantly lower regardless whether i.th. MTX had been administered or not ( figure 3) . The proportional hazard model with an interaction term between rituximab and prophylaxis adjusted for the IPI-factors confirmed a relevant interaction (RR=6.1). Thus, no effect of i.th. MTX on any type of CNS event was detectable when modern immunochemotherapy including rituximab was administered.
Discussion
In patients with non-Hodgkin lymphoma CNS relapse was reported in 0 to 39% depending on the histologic subtypes represented in the study population. Animal experiments have shown that the levels of rituximab measured in the cerebrospinal fluid (CSF) are distinctly lower (0.1-1.7%) than the corresponding serum levels. 23 A phase I study demonstrated that i.th. administration of rituximab by Ommaya reservoir is feasible, safe, and efficacious. 24 There is evidence that patients with CNS lymphoma have a disrupted blood/brain barrier and therefore also may benefit from intravenous rituximab.
25,26
Whether the prophylactic effect of rituximab on CNS disease represents a direct effect to the CNS remains elusive. We consider it more likely that the reduction of CNS events in the rituximab arms of the RICOVER-60 trial reflects the improved systemic efficacy of R-CHOP-14.
Data from GELA and the DSHNHL suggest that administration of cytotoxic agents crossing the For personal use only. on March 30, 2017. by guest www.bloodjournal.org From blood/brain barrier should be more effective in reducing CNS events than the addition of rituximab to chemotherapy alone. A study from the Royal Marsden Hospital reported an exquisitely low incidence of CNS relapse (1.1%) in patients who to large parts had received both etoposide and rituximab. 27 We did not see any CNS event in patients treated with rituximab in the phase II MegaCHOEP studies. On the other hand, a small phase II study indicates that CNS relapses continue to occur with R-CHOEP-14.
28
The analysis of risk factors for CNS events in our study confirmed previous observations that involvement of more than one extranodal site and elevated LDH are independent predictors for CNS disease. MTX was administered or not and it is highly questionable if this would justify prophylaxis in any risk group. This holds particularly true because many patients were not in CR at the time of CNS progression and/or showed systemic relapse. Such patients will be doing poor anyway. For the 4.8% of patients treated with R-CHOP-14 who belonged to the high-risk group as defined by our COX regression analysis (involvement of >1 extranodal site, elevated LDH, poor ECOG performance status), the probability of CNS disease seems substantial (33.5% at 2 years). We still hesitate to recommend i.th. MTX to this or any other "high-risk" population because 3 out of 7 patients (43%) belonging to our high-risk group had received i.th. MTX but still relapsed to the CNS, shedding doubt on the efficacy of i.th. MTX in general. Whether other prophylactic measures are more effective and should be offered to high-risk patients cannot be answered by our study. In any case, between 4 and 6 patients would need CNS prophylaxis to prevent one CNS relapse.
We conclude that the addition of rituximab to CHOP reduces the risk of CNS disease in elderly patients with DLBCL. Patients with involvement of more than one extranodal site, elevated LDH, and poor performance status remain at risk for CNS events also if rituximab is added to chemotherapy. I.th. MTX significantly reduced CNS events in patients with involvement of bone marrow, testes, head, or adjacent lymph nodes if no rituximab was administered. In patients treated with R-CHOP-14 the incidence of CNS disease overall and in this risk group was low; i.th.
MTX failed to reduce the risk with the possible exception of patients with testicular involvement.
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